Login | Register
 Username 
 Password 
 
Login

HIV ATLAS

HIV :: TUBERCULOSIS :: MALARIA

Primary links

  • HOME
    • About Us
    • Contact Us
  • CLASSIFIED BLOGS
  • JOBS
  • EVENTS
  • LINKS
  • DAILY WIRE
  • VIDEOS
  |  
Home Blogs bob's blog

Featured Jobs

  • Dean - Indian Institute of Advanced Nursing, Chennai
  • Research Capacity Building Advisor, Haiti
  • Vacancy announcement in Afghanistan
  • Chief of Party- Kenya Public Health
  • Chief of Party/Technical Advisor, HIV-Haiti
  • DEPUTY CHIEF OF PARTY, RUSSIA
  • CHIEF OF PARTY, RUSSIA
  • Chief of Party, India
  • Chief of Party- Kenya
  • Namibia Department of Defense Program Lead

Events

  • 11th International Workshop on Adverse Drug Reactions & Co-Morbidities in HIV Philadelphia, PA, USA, 28 October 2009 (AEGiS)
  • Aids in Culture VI: Explorations in the Cultural History of AIDS International Conference. Mexico City, 9 - 14 December 2010
  • Sexual Health Conference in Bali, May 4-6
  • CBCP calls for summit on HIV-AIDS - ABS CBN News
  • ASEAN youth meet to map out HIV/AIDS prevention activities - Xinhua
  • Gujarat - Get togehter 3000 PLHAs at Capital of Gujarat
  • International Symposium on HIV & Emerging Infectious Diseases.
  • India NGO Awards 2009
  • HIV Congress 2010
  • January 2010 Free POZ Weekend Seminar in LA!

Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.

Submitted by bob on Sat, 07/04/2009 - 17:12
  • Abstracts and Research
  • World Wide

Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. - Related Articles
Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.
HIV Clin Trials. 2009 Jan-Feb;10(1):1-12
Authors: Hill A, Sawyer W, Gazzard B
INTRODUCTION: Treatment with ritonavir-boosted protease inhibitors or efavirenz and nucleoside analogues leads to rises in lipids, which might contribute to cardiovascular risk. METHOD: A MEDLINE search for clinical trials of first-line HAART with standardized 48-week lipids data available for combinations of two nucleoside analogues identified 13 with additional boosted protease inhibitor (PI/r) regimens (n = 5,281) and two with efavirenz (n = 1,087). Inverse-variance weighting was used to provide estimates of combined 48-week elevations in each lipid parameter. RESULTS: The trials were well balanced for mean baseline total cholesterol (155 mg/dL), triglycerides (125 mg/dL), LDL (95 mg/dL), and HDL (37 mg/dL). The PIs showed two different types of lipid elevations: Group 1: saquinavir/r, atazanavir/r, and darunavir/r; and Group 2: lopinavir/ritonavir and fosamprenavir/r. There were greater elevations in total cholesterol and triglycerides for Group 2 compared to Group 1 but no differences in LDL or HDL between Group 1 and Group 2. Patients treated with efavirenz showed similar rises in total cholesterol and LDL compared with the PIs in Group 2 but showed smaller rises than in Group 1. In addition, patients treated with abacavir/lamivudine, zidovudine/lamiuvudine, or stavudine/lamivudine showed significantly higher elevations in all four lipid parameters, compared with patients given tenofovir/emtricitabine. CONCLUSION: There is a wide range of lipid elevations during 48 weeks of first-line HAART, which depends on the choice of antiretrovirals used.
PMID: 19362991 [PubMed - indexed for MEDLINE]
[PubMed-HIV]

  • bob's blog
  • Login or register to post comments
  • Printer-friendly version

RESOURCES

  • AEGiS
  • AIDS.gov
  • AIDS_ASIA
  • AIDS-INDIA
  • AIDSPORTAL.org
  • About.com
  • Aids-write.org
  • All Africa.com
  • CDC
  • Children & HIV
  • Clinical Care Options HIV
  • DailyMed
  • EATG
  • EBLING LIBRARY
  • Eldis-Jobs
  • Eldis.org
  • GNP Latest news
  • Google-Homophobia
  • Google-HIV Baby-sitting
  • Google HIV NEWS
  • Google MALARIA NEWS
  • Google TB NEWS
  • HIV Law Project
  • HIV Positive Dating
  • HIV Twinning News
  • Hivdatfla
  • Hivsnp
  • IAVI
  • IFANET-INDIA
  • IGIB/CSIR
  • DevNetJobs
  • Indeed.com
  • Iran HIV AIDS
  • Juju-HIV
  • Kaiser-Child health
  • Kaiser HIV/AIDS
  • Kaiser Malaria
  • Kaiser-Tuberculosis
  • Kaiser-U.S. HIV
  • Medical News-HIV
  • Medical News-TB
  • MEDSCAPE
  • Medsin Manchester
  • National AIDS Map
  • Nature Jobs
  • Nets at Harvard University
  • NIAID
  • NMAC
  • NIH.gov
  • NMPrev
  • OpenSource.org.in
  • Oxfam Jobs
  • Partners Zambia
  • Policy and Ethics
  • PozHealth
  • PubMed-HIV
  • PubMed-Malaria
  • RBM Topline Stories
  • SAATHII
  • Save The Children
  • Treatment Action Campaign
  • Tuberculous-Meningitis
  • Tuberculosis-Pulmonary
  • UKLug-HIV
  • UKLug-Tuberculosis
  • UNAIDS-JOBS
  • UNAIDS-SERVICE
  • UNICEF News
  • UNICEF Photo Essays
  • WHO
  • Women & HIV
Every 9½ minutes someone in the US is infected with HIV. Act Against AIDS. Get the facts: NineAndaHalfMinutes.org

ABOUT HIV ATLAS

A Social Media initiative that aims to Collect, Collate, Classify and Disseminate the information on HIV, TB & Malaria so that people living with HIV and the people working in the field can be on top of the information generating from more than 700 online and offline resources.

HIV ATLAS provides its users a unique way to be on top of information ranging from common living to funding, jobs, events and much more absolutely free of charge. We encourage Employers to post their Job opportunities in our featured Jobs cateogry to reach out to more than 40000 subscribers daily.

JOIN HIV ATLAS

HIV ATLAS welcomes content contributions and strongly encourages all sector participants to actively share their advertisements.

You can contribute and engage by:
- Creating your profile
- Posting your classified advertisements
- sharing information about Jobs, Events, Funding etc with us
- sharing information about any online resource you want us to include
- creating your resume for potential employers to have a look in.

NEWLETTER SUBSCRIPTIONS

Manage your newsletter subscriptions
Select the newsletter(s) to which you want to subscribe or unsubscribe.
  Copyright © 2004-2009 HIV ATLAS.org. All rights reserved. | Legal | Contact Powered by Halosys Technologies Inc.  

Disclaimer: This site contains HIV prevention messages that may not be appropriate for all audiences.